|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 121.1 USD | -1.37% |
|
-9.25% | -3.83% |
| 16/05 | Morgan Stanley Adjusts Ascendis Pharma Price Target to $140 From $116, Maintains Equal Weight Rating | MT |
| 14/05 | US Equity Markets Close Higher Tuesday as Producer Prices Rise | MT |
Ascendis Pharma A/S reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was EUR 95.89 million compared to EUR 33.59 million a year ago. Net loss was EUR 131.04 million compared to EUR 110.91 million a year ago.
Basic loss per share from continuing operations was EUR 2.3 compared to EUR 1.98 a year ago. Diluted loss per share from continuing operations was EUR 2.3 compared to EUR 1.98 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -3.83% | 7.04B | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
ASCENDIS PHARMA A/S 
